Technical Analysis for MYOK - MyoKardia, Inc.

Grade Last Price % Change Price Change
grade B 54.5 0.31% 0.17
MYOK closed up 0.31 percent on Wednesday, March 20, 2019, on 56 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical MYOK trend table...

Date Alert Name Type % Chg
Mar 20 Wide Bands Range Expansion 0.00%
Mar 20 Overbought Stochastic Strength 0.00%
Mar 20 Up 3 Days in a Row Strength 0.00%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 0.31%
Mar 19 Boomer Buy Setup Bullish Swing Setup 0.31%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.31%
Mar 19 Narrow Range Bar Range Contraction 0.31%
Mar 19 NR7 Range Contraction 0.31%
Mar 19 Inside Day Range Contraction 0.31%
Mar 19 Wide Bands Range Expansion 0.31%

Older signals for MYOK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
MyoKardia, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops DCM-1, a product candidate that treats heritable dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. MyoKardia, Inc. has a strategic collaboration with Sanofi S.A. The company was founded in 2012 and is headquartered in South San Francisco, California.
Medical Specialties Anatomy Sports Medicine Cardiomyopathy Muscular System
Is MYOK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.78
52 Week Low 39.01
Average Volume 549,247
200-Day Moving Average 52.8943
50-Day Moving Average 45.49
20-Day Moving Average 49.636
10-Day Moving Average 52.577
Average True Range 2.4593
ADX 37.51
+DI 29.0026
-DI 10.1607
Chandelier Exit (Long, 3 ATRs ) 48.0721
Chandelier Exit (Short, 3 ATRs ) 49.8379
Upper Bollinger Band 57.4194
Lower Bollinger Band 41.8526
Percent B (%b) 0.81
BandWidth 31.361915
MACD Line 2.6859
MACD Signal Line 2.2791
MACD Histogram 0.4068
Fundamentals Value
Market Cap 1.72 Billion
Num Shares 31.5 Million
EPS -0.65
Price-to-Earnings (P/E) Ratio -83.85
Price-to-Sales 26.88
Price-to-Book 9.37
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.66
Resistance 3 (R3) 56.74 56.09 56.30
Resistance 2 (R2) 56.09 55.54 56.06 56.18
Resistance 1 (R1) 55.30 55.20 55.70 55.22 56.06
Pivot Point 54.65 54.65 54.85 54.62 54.65
Support 1 (S1) 53.86 54.10 54.26 53.78 52.94
Support 2 (S2) 53.21 53.76 53.18 52.82
Support 3 (S3) 52.42 53.21 52.70
Support 4 (S4) 52.34